NCT06853080View on ClinicalTrials.gov

Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Atypical Teratoid/Rhabdoid Tumors (AT/RTs)Central Nervous System (CNS) Tumors
Interventions
DRUG

Bortezomib

4 cycles of Bortezomib treatment, with each cycle include 8 doses of Bortezomib at 1.3 mg/m2

Trial Locations (1)

11031

Taipei Medical University Hospital, Taipei

All Listed Sponsors
lead

Taipei Medical University

OTHER